TG Therapeutics, Inc. (NASDAQ:TGTX) announced the publication of clinical data from a Phase 1/2 trial of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) previously exposed to rituximab. The data demonstrates single agent TG-1101 to be well tolerated with the most common adverse event observed being grade 1/2 infusion related reactions (IRR), with no grade 3/4 IRRs. TG-1101 monotherapy was active, with a 45% overall response rate (ORR) observed among heavily pretreated patients with NHL and CLL, including those who were refractory to prior anti-CD20 based therapy. These data are described further in the manuscript titled, “A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab,” which was published online in the British Journal of Haematology.
“We want to thank Dr. Owen O’Connor, and the team from Columbia Presbyterian Medical Center and the Center for Lymphoid Malignancies for their work on this Phase 1/2 trial of single agent TG-1101 and congratulate them on the publication of these data. Since the inception of our Company, we have been focused on developing best-in-class agents with the goal of building novel combination therapies. This single agent data illustrates that TG-1101 is a safe and highly-active anti-CD20 monoclonal antibody on top of which additional treatments can be layered.
At the movement TG Therapeutics, Inc. (NASDAQ:TGTX) is under coverage by number of analysts. Buy rating has been given by 3 analysts to the company stock whereas no analyst given UNDERPERFORM rating to stock and no analyst given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Buy and their mean rating for the stock is 1.40 on scale of 1-5. Analysts mean target price for TG Therapeutics, Inc. (NASDAQ:TGTX) is $20.80 while their mean recommendation is 1.40 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved up 1.08% to end the day at $4.70. The current share price indicate that stock is -55.24% away from its one year high and is moving 14.63% ahead of its 52-week low.
Enable Midstream Partners, LP (NYSE:ENBL) reported that its net income attributable to common and subordinated units for fourth quarter 2016 was $59 million, a decrease of $6 million, or 9 percent, compared to $65 million for fourth quarter 2015. Earnings per unit declined to $0.14 from $0.15 last year. Revenues were $614 million, an increase of $48 million compared to $566 million in the prior year.
On 21 February 2017, Enable Midstream Partners, LP (NYSE:ENBL) shares moved to $16.46 after starting the day at $16.55. Number of analysts are covering this stock and currently stock has got OUTPERFORM rating from 1 analyst of Thomson Reuters, 6 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for ENBL is $16.33 while analysts mean recommendation is 2.50.